AptarGroup (ATR)
Market Price (7/6/2026): $126.985 | Market Cap: $8.1 BilSector: Materials | Industry: Metal, Glass & Plastic Containers
AptarGroup (ATR)
Market Price (7/6/2026): $126.985Market Cap: $8.1 BilSector: MaterialsIndustry: Metal, Glass & Plastic Containers
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16% Low stock price volatilityVol 12M is 26% Megatrend and thematic driversMegatrends include Circular Economy & Recycling, Sustainable Consumption, and Precision Medicine. Themes include Sustainable Packaging Materials, Show more. | Weak multi-year price returns2Y Excs Rtn is -46%, 3Y Excs Rtn is -56% | Key risksATR key risks include [1] a significant, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Low stock price volatilityVol 12M is 26% |
| Megatrend and thematic driversMegatrends include Circular Economy & Recycling, Sustainable Consumption, and Precision Medicine. Themes include Sustainable Packaging Materials, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -46%, 3Y Excs Rtn is -56% |
| Key risksATR key risks include [1] a significant, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
AptarGroup (ATR) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Flat Core Sales. AptarGroup reported an 11% increase in reported sales to $982.9 million for fiscal Q1 2026, which surpassed analyst expectations. However, core sales remained flat, indicating a lack of organic growth. Adjusted earnings per share (EPS) for the quarter were $1.19, an 8% decrease year-over-year at constant currency, despite exceeding the analyst consensus of $1.15. The adjusted EBITDA margin also saw a decline to 19.2% from 20.7% in the prior year, attributed to a less favorable product mix and operational challenges within the Beauty and Closures segments.
2. Offsetting Performance Across Business Segments. While the Pharma segment experienced a 1% decline in core sales, primarily due to emergency medicine destocking impacting prescription division sales by 5%, this was largely offset by robust growth in the injectables division. The injectables business achieved a strong 20% increase in core sales, driven by sustained demand for components used in GLP-1 therapies and biologics. Additionally, consumer dispensing, particularly in prestige fragrance and beverage applications within the Beauty and Closures segments, contributed positively to volume growth, balancing some of the weaker areas.
Show more
AptarGroup (ATR) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Flat Core Sales. AptarGroup reported an 11% increase in reported sales to $982.9 million for fiscal Q1 2026, which surpassed analyst expectations. However, core sales remained flat, indicating a lack of organic growth. Adjusted earnings per share (EPS) for the quarter were $1.19, an 8% decrease year-over-year at constant currency, despite exceeding the analyst consensus of $1.15. The adjusted EBITDA margin also saw a decline to 19.2% from 20.7% in the prior year, attributed to a less favorable product mix and operational challenges within the Beauty and Closures segments.
2. Offsetting Performance Across Business Segments. While the Pharma segment experienced a 1% decline in core sales, primarily due to emergency medicine destocking impacting prescription division sales by 5%, this was largely offset by robust growth in the injectables division. The injectables business achieved a strong 20% increase in core sales, driven by sustained demand for components used in GLP-1 therapies and biologics. Additionally, consumer dispensing, particularly in prestige fragrance and beverage applications within the Beauty and Closures segments, contributed positively to volume growth, balancing some of the weaker areas.
Show more
Updated on 7/1/2026
AptarGroup (ATR) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Flat Core Sales. AptarGroup reported an 11% increase in reported sales to $982.9 million for fiscal Q1 2026, which surpassed analyst expectations. However, core sales remained flat, indicating a lack of organic growth. Adjusted earnings per share (EPS) for the quarter were $1.19, an 8% decrease year-over-year at constant currency, despite exceeding the analyst consensus of $1.15. The adjusted EBITDA margin also saw a decline to 19.2% from 20.7% in the prior year, attributed to a less favorable product mix and operational challenges within the Beauty and Closures segments.
2. Offsetting Performance Across Business Segments. While the Pharma segment experienced a 1% decline in core sales, primarily due to emergency medicine destocking impacting prescription division sales by 5%, this was largely offset by robust growth in the injectables division. The injectables business achieved a strong 20% increase in core sales, driven by sustained demand for components used in GLP-1 therapies and biologics. Additionally, consumer dispensing, particularly in prestige fragrance and beverage applications within the Beauty and Closures segments, contributed positively to volume growth, balancing some of the weaker areas.
3. Consistent Shareholder Returns and Stable Fiscal Q2 2026 Outlook. AptarGroup demonstrated a commitment to shareholder value by repurchasing 707 thousand shares for $100 million during fiscal Q1 2026 and declaring a quarterly cash dividend of $0.48 per share. For fiscal Q2 2026, management provided an adjusted EPS guidance range of $1.32 to $1.40, suggesting a stable, but not rapidly accelerating, short-term earnings trajectory. This combination of returning capital to shareholders and a conservative outlook likely contributed to the stock maintaining its level.
4. Persistent Macroeconomic Headwinds. The broader market sentiment during fiscal Q2 2026 was influenced by ongoing macroeconomic uncertainty. Geopolitical conflicts, such as the Middle East conflict, led to concerns over higher energy costs and potential supply-chain disruptions. Additionally, persistent inflationary pressures, with headline CPI projected to increase to 3.5% in 2026, contributed to a cautious investment environment. These external factors likely acted as a ceiling on AptarGroup's stock performance, preventing significant upward movement despite some positive internal developments.
Show less
AptarGroup (ATR) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Flat Core Sales. AptarGroup reported an 11% increase in reported sales to $982.9 million for fiscal Q1 2026, which surpassed analyst expectations. However, core sales remained flat, indicating a lack of organic growth. Adjusted earnings per share (EPS) for the quarter were $1.19, an 8% decrease year-over-year at constant currency, despite exceeding the analyst consensus of $1.15. The adjusted EBITDA margin also saw a decline to 19.2% from 20.7% in the prior year, attributed to a less favorable product mix and operational challenges within the Beauty and Closures segments.
2. Offsetting Performance Across Business Segments. While the Pharma segment experienced a 1% decline in core sales, primarily due to emergency medicine destocking impacting prescription division sales by 5%, this was largely offset by robust growth in the injectables division. The injectables business achieved a strong 20% increase in core sales, driven by sustained demand for components used in GLP-1 therapies and biologics. Additionally, consumer dispensing, particularly in prestige fragrance and beverage applications within the Beauty and Closures segments, contributed positively to volume growth, balancing some of the weaker areas.
3. Consistent Shareholder Returns and Stable Fiscal Q2 2026 Outlook. AptarGroup demonstrated a commitment to shareholder value by repurchasing 707 thousand shares for $100 million during fiscal Q1 2026 and declaring a quarterly cash dividend of $0.48 per share. For fiscal Q2 2026, management provided an adjusted EPS guidance range of $1.32 to $1.40, suggesting a stable, but not rapidly accelerating, short-term earnings trajectory. This combination of returning capital to shareholders and a conservative outlook likely contributed to the stock maintaining its level.
4. Persistent Macroeconomic Headwinds. The broader market sentiment during fiscal Q2 2026 was influenced by ongoing macroeconomic uncertainty. Geopolitical conflicts, such as the Middle East conflict, led to concerns over higher energy costs and potential supply-chain disruptions. Additionally, persistent inflationary pressures, with headline CPI projected to increase to 3.5% in 2026, contributed to a cautious investment environment. These external factors likely acted as a ceiling on AptarGroup's stock performance, preventing significant upward movement despite some positive internal developments.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 1.2% change in ATR stock from 3/31/2026 to 7/5/2026 was primarily driven by a 2.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7052026 | Change |
|---|---|---|---|
| Stock Price ($) | 125.52 | 126.98 | 1.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,777 | 3,873 | 2.5% |
| Net Income Margin (%) | 10.4% | 10.0% | -4.0% |
| P/E Multiple | 20.8 | 21.0 | 1.3% |
| Shares Outstanding (Mil) | 65 | 64 | 1.5% |
| Cumulative Contribution | 1.2% |
Market Drivers
3/31/2026 to 7/5/2026| Return | Correlation | |
|---|---|---|
| ATR | 1.2% | |
| Market (SPY) | 14.5% | 20.0% |
| Sector (XLB) | 4.1% | 50.3% |
Fundamental Drivers
The 4.9% change in ATR stock from 12/31/2025 to 7/5/2026 was primarily driven by a 10.9% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7052026 | Change |
|---|---|---|---|
| Stock Price ($) | 121.01 | 126.98 | 4.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,663 | 3,873 | 5.7% |
| Net Income Margin (%) | 11.5% | 10.0% | -12.8% |
| P/E Multiple | 19.0 | 21.0 | 10.9% |
| Shares Outstanding (Mil) | 66 | 64 | 2.6% |
| Cumulative Contribution | 4.9% |
Market Drivers
12/31/2025 to 7/5/2026| Return | Correlation | |
|---|---|---|
| ATR | 4.9% | |
| Market (SPY) | 9.5% | 35.9% |
| Sector (XLB) | 15.2% | 55.8% |
Fundamental Drivers
The -17.7% change in ATR stock from 6/30/2025 to 7/5/2026 was primarily driven by a -23.8% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7052026 | Change |
|---|---|---|---|
| Stock Price ($) | 154.21 | 126.98 | -17.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,555 | 3,873 | 8.9% |
| Net Income Margin (%) | 10.4% | 10.0% | -4.1% |
| P/E Multiple | 27.6 | 21.0 | -23.8% |
| Shares Outstanding (Mil) | 66 | 64 | 3.5% |
| Cumulative Contribution | -17.7% |
Market Drivers
6/30/2025 to 7/5/2026| Return | Correlation | |
|---|---|---|
| ATR | -17.7% | |
| Market (SPY) | 21.6% | 25.8% |
| Sector (XLB) | 20.2% | 50.6% |
Fundamental Drivers
The 13.9% change in ATR stock from 6/30/2023 to 7/5/2026 was primarily driven by a 43.9% change in the company's Net Income Margin (%).| (LTM values as of) | 6302023 | 7052026 | Change |
|---|---|---|---|
| Stock Price ($) | 111.46 | 126.98 | 13.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,337 | 3,873 | 16.0% |
| Net Income Margin (%) | 6.9% | 10.0% | 43.9% |
| P/E Multiple | 31.5 | 21.0 | -33.1% |
| Shares Outstanding (Mil) | 65 | 64 | 2.1% |
| Cumulative Contribution | 13.9% |
Market Drivers
6/30/2023 to 7/5/2026| Return | Correlation | |
|---|---|---|
| ATR | 13.9% | |
| Market (SPY) | 74.0% | 44.4% |
| Sector (XLB) | 32.5% | 55.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ATR Return | -10% | -9% | 14% | 29% | -21% | 4% | -2% |
| Peers Return | 20% | -8% | 6% | -1% | -5% | 19% | 32% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| ATR Win Rate | 42% | 42% | 67% | 83% | 50% | 57% | |
| Peers Win Rate | 65% | 42% | 52% | 50% | 53% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| ATR Max Drawdown | -27% | -24% | -9% | -11% | -30% | -23% | |
| Peers Max Drawdown | -15% | -33% | -24% | -22% | -27% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WST, SLGN, AMCR, CCK, SON. See ATR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/2/2026 (YTD)
How Low Can It Go
| Event | ATR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -21.9% | -24.5% |
| % Gain to Breakeven | 28.1% | 32.4% |
| Time to Breakeven | 142 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.0% | -33.7% |
| % Gain to Breakeven | 37.0% | 50.9% |
| Time to Breakeven | 101 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -17.2% | -19.2% |
| % Gain to Breakeven | 20.8% | 23.8% |
| Time to Breakeven | 88 days | 105 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -12.4% | -6.8% |
| % Gain to Breakeven | 14.2% | 7.3% |
| Time to Breakeven | 25 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -19.0% | -17.9% |
| % Gain to Breakeven | 23.4% | 21.8% |
| Time to Breakeven | 81 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -13.4% | -15.4% |
| % Gain to Breakeven | 15.4% | 18.2% |
| Time to Breakeven | 20 days | 125 days |
In The Past
AptarGroup's stock fell -9.1% during the 2025 US Tariff Shock. Such a loss loss requires a 10.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ATR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -21.9% | -24.5% |
| % Gain to Breakeven | 28.1% | 32.4% |
| Time to Breakeven | 142 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.0% | -33.7% |
| % Gain to Breakeven | 37.0% | 50.9% |
| Time to Breakeven | 101 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -40.2% | -53.4% |
| % Gain to Breakeven | 67.3% | 114.4% |
| Time to Breakeven | 401 days | 1085 days |
In The Past
AptarGroup's stock fell -9.1% during the 2025 US Tariff Shock. Such a loss loss requires a 10.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AptarGroup (ATR)
AptarGroup (ATR) is a global leader in providing innovative dispensing, sealing, and material science solutions. The company designs and manufactures a wide range of sophisticated packaging components that enable precise and controlled delivery of products across numerous consumer and healthcare applications. Essentially, AptarGroup helps brand owners deliver their products effectively and safely to end-users through its specialized engineering and manufacturing capabilities.
The company operates through three primary segments, each serving distinct markets with tailored products. Its Pharma segment offers critical components like metered dose inhaler valves for respiratory ailments, pumps for nasal allergy treatments, and injectable primary packaging components for prescription drugs, consumer healthcare, and injectable markets. The Beauty + Home segment supplies pumps, closures, aerosol valves, accessories, and decorative components primarily for beauty, personal care, and home care products. Lastly, the Food + Beverage segment provides a variety of dispensing and non-dispensing closures, elastomeric flow control components, and spray pumps for the food and beverage industries.
AptarGroup serves a diverse global customer base through its own sales force and a network of independent representatives and distributors across North America, Europe, Asia, and Latin America. The company also emphasizes innovation and sustainability, engaging in strategic partnerships to develop ultra-pure recycled materials for its applications and collaborating on digital therapy platforms to enhance solutions in the healthcare space.
AI Analysis | Feedback
Here are a couple of analogies to describe AptarGroup (ATR):
-
AptarGroup is like the Intel Inside for the caps, pumps, and spray nozzles on countless everyday products, from personal care items to prescription medications.
-
They are similar to 3M, but specifically focused on engineered dispensing, sealing, and material science solutions for products ranging from shampoo to nasal allergy sprays and food packaging.
AI Analysis | Feedback
- Dispensing Pumps: Components that facilitate controlled dispensing of liquids, used in pharmaceuticals, beauty, personal care, and food/beverage products.
- Closures: A variety of dispensing and non-dispensing caps and tops for packaging in food, beverage, personal care, and home care markets.
- Aerosol Valves: Essential mechanisms for delivering products in aerosol form, found in beauty, home care, food, and beverage applications.
- Metered Dose Inhaler Valves: Specialized valves that deliver precise dosages of medication for respiratory ailments, such as asthma and COPD.
- Injectable Primary Packaging Components: Elastomeric components used in pharmaceutical packaging for injectable drugs.
- Active Material Science Solutions: Innovative solutions that incorporate advanced materials to enhance product performance, protection, or delivery, particularly in pharmaceutical applications.
- Elastomeric Flow Control Components: Flexible components designed to regulate or control the flow of liquids, primarily within the food and beverage industry.
- Sealing Solutions: Products designed to create effective seals for various packaging, ensuring product integrity and preventing leakage.
AI Analysis | Feedback
AptarGroup (ATR) sells its products primarily to other companies (Business-to-Business or B2B) rather than directly to individuals.
Based on the provided background information, the specific names of AptarGroup's major customer companies are not disclosed. However, the company provides its dispensing, sealing, and material science solutions to manufacturers and brands across several key markets:
- Pharmaceutical Companies: These customers utilize Aptar's solutions for prescription drugs, consumer health care products, and injectables, including pumps for nasal allergy treatments, metered dose inhaler valves for respiratory ailments, and elastomer for injectable primary packaging components.
- Beauty, Personal Care, and Home Care Brands: Aptar supplies these customers with pumps, closures, aerosol valves, accessories, and sealing solutions for a wide range of products such as cosmetics, perfumes, lotions, shampoos, body washes, and household cleaning products.
- Food and Beverage Manufacturers: For this market, Aptar offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves used in various food and beverage products.
AI Analysis | Feedback
```html
- PureCycle Technologies LLC (NASDAQ: PCT)
AI Analysis | Feedback
Stephan B. Tanda, President and Chief Executive Officer
Prior to joining Aptar in February 2017, Mr. Tanda served as an Executive Managing Board Director at Royal DSM NV, overseeing its global Nutrition business and Pharma joint ventures and business interests in the Americas. His career spans over 25 years, during which he lived and worked in seven countries, holding leadership roles at DuPont and as President and CEO of Freudenberg Nonwovens Group. He has experience in developing organizations and businesses, achieving sales and profit growth through both organic means and acquisitions. Mr. Tanda also served as a director of Patheon NV, a pharmaceutical development and manufacturing services company, which was sold to Thermo Fisher Scientific in 2017.
Vanessa Kanu, Executive Vice President and Chief Financial Officer
Ms. Kanu became Aptar's Executive Vice President and Chief Financial Officer on January 1, 2025. She brings over 25 years of experience with global multi-billion dollar and publicly traded companies. Most recently, she served as CFO of TELUS International, where she led the largest technology IPO in the history of the Toronto Stock Exchange and was involved in the acquisition and integration of several strategic acquisitions. She previously held the CFO role at Mitel Networks Corporation. Ms. Kanu also serves on the Board of Directors of Manulife Financial Corporation.
Gael Touya, President, Aptar Pharma
Mr. Touya was named President of Aptar Pharma in September 2018. He has over 30 years of experience with Aptar, having served as President of the Food + Beverage segment and overseeing its European operations prior to his current role. He has held various sales, business development, and general manager positions across all of Aptar's business segments in Europe and Asia, including a multi-year assignment in China.
Marc Prieur, President, Aptar Beauty
Mr. Prieur was appointed President of Aptar Beauty in December 2019. His career with Aptar spans over 20 years, during which he has lived and worked in Europe, the United States, and China. His experience includes leadership roles in Sales & Operations for Consumer Health Care in Europe and Aptar's Pharma business in Asia. He also previously served as President of Aptar Food + Beverage and as Vice President of Operational Excellence for the company.
Xiangwei Gong, Executive Vice President, Strategic Group Development and President, Aptar Asia
Ms. Gong joined Aptar in October 2018 as President, Aptar Asia. She is an entrepreneurial leader with over 25 years of experience in B2B and B2C businesses, with a strong background in the Beauty, Personal Care, Nutrition, and Pharma industries. She has lived and worked in several countries, holding increasingly senior roles at Roche Vitamins and Royal DSM.
Prior to joining Aptar in February 2017, Mr. Tanda served as an Executive Managing Board Director at Royal DSM NV, overseeing its global Nutrition business and Pharma joint ventures and business interests in the Americas. His career spans over 25 years, during which he lived and worked in seven countries, holding leadership roles at DuPont and as President and CEO of Freudenberg Nonwovens Group. He has experience in developing organizations and businesses, achieving sales and profit growth through both organic means and acquisitions. Mr. Tanda also served as a director of Patheon NV, a pharmaceutical development and manufacturing services company, which was sold to Thermo Fisher Scientific in 2017.
Vanessa Kanu, Executive Vice President and Chief Financial Officer
Ms. Kanu became Aptar's Executive Vice President and Chief Financial Officer on January 1, 2025. She brings over 25 years of experience with global multi-billion dollar and publicly traded companies. Most recently, she served as CFO of TELUS International, where she led the largest technology IPO in the history of the Toronto Stock Exchange and was involved in the acquisition and integration of several strategic acquisitions. She previously held the CFO role at Mitel Networks Corporation. Ms. Kanu also serves on the Board of Directors of Manulife Financial Corporation.
Gael Touya, President, Aptar Pharma
Mr. Touya was named President of Aptar Pharma in September 2018. He has over 30 years of experience with Aptar, having served as President of the Food + Beverage segment and overseeing its European operations prior to his current role. He has held various sales, business development, and general manager positions across all of Aptar's business segments in Europe and Asia, including a multi-year assignment in China.
Marc Prieur, President, Aptar Beauty
Mr. Prieur was appointed President of Aptar Beauty in December 2019. His career with Aptar spans over 20 years, during which he has lived and worked in Europe, the United States, and China. His experience includes leadership roles in Sales & Operations for Consumer Health Care in Europe and Aptar's Pharma business in Asia. He also previously served as President of Aptar Food + Beverage and as Vice President of Operational Excellence for the company.
Xiangwei Gong, Executive Vice President, Strategic Group Development and President, Aptar Asia
Ms. Gong joined Aptar in October 2018 as President, Aptar Asia. She is an entrepreneurial leader with over 25 years of experience in B2B and B2C businesses, with a strong background in the Beauty, Personal Care, Nutrition, and Pharma industries. She has lived and worked in several countries, holding increasingly senior roles at Roche Vitamins and Royal DSM.
AI Analysis | Feedback
The key risks to AptarGroup's business include significant headwinds in its Pharma segment, particularly concerning emergency medicine products, ongoing margin volatility and operational disruptions within its Beauty + Home and Food + Beverage segments, and broad exposure to geopolitical, tariff, and foreign exchange risks inherent in its global operations.
-
Headwinds in the Pharma Segment, especially Emergency Medicine: AptarGroup faces a substantial risk due to a decline in demand for emergency medicine products, which are a highly profitable part of its Pharma segment. This is projected to result in a significant revenue headwind for 2026, with an anticipated 35% reduction in revenues from such products and a $65 million revenue drag for the year, primarily affecting the first half. The impact is exacerbated by inventory destocking by customers. While the Pharma segment remains dominant in high-margin areas like nasal drug delivery and injectables, this specific downturn is a notable challenge to the company's profitability and growth.
-
Margin Volatility and Operational Disruptions in Beauty + Home and Food + Beverage Segments: The company's profitability has been impacted by less favorable product mix, higher production costs, environmental upgrades at facilities, and unscheduled equipment maintenance, particularly within its Beauty + Home (referred to as Beauty and Closures in some reports) and Food + Beverage (Closures) segments. These operational disruptions and cost pressures have contributed to adjusted EBITDA margin declines and are expected to continue creating headwinds, though management anticipates some abatement in the first half of 2026.
-
Geopolitical, Tariff, and Foreign Exchange Risks: With over 50% of its revenue derived internationally, AptarGroup is highly susceptible to global trade policies, tariffs, currency fluctuations, and export controls on drug delivery technologies. The imposition of significant tariffs, potential retaliatory measures, and general global trade tensions could lead to increased costs for raw materials, disrupt supply chains, and reduce demand for its products. Additionally, movements in exchange rates, particularly for major currencies like the Euro, Chinese Yuan, and Brazilian Real, can materially impact the company's financial results. Geopolitical conflicts also pose an indirect risk by affecting customer demand and supply chain stability.
AI Analysis | Feedback
null
AI Analysis | Feedback
AptarGroup, Inc. (ATR) provides a diverse range of dispensing, sealing, and material science solutions across three primary segments: Pharma, Beauty + Home, and Food + Beverage. The addressable markets for their main products and services are substantial globally.
Pharma Segment
- Nasal Spray Pumps and Nasal Drug Delivery Technology: The global nasal drug delivery technology market was valued at USD 71.9 billion in 2023 and is estimated to grow at a 6.8% CAGR from 2024 to 2032, reaching USD 129.5 billion by 2032. Specifically, the global nasal spray market was valued at USD 25.76 billion in 2024 and is expected to reach USD 43.29 billion by 2032. The global sterile nasal spray pump market size is anticipated to be worth USD 0.11 billion in 2026 and is expected to reach USD 0.16 billion by 2035.
- Metered Dose Inhaler Valves: The global metered dose inhalers market size was valued at USD 10.1 billion in 2024 and is projected to reach USD 18.4 billion by 2034. Another estimate indicates the global metered dose inhalers market size is expected to grow from USD 26.22 billion in 2024 to USD 42.02 billion by 2035.
- Injectable Primary Packaging Components: The global injectable drug packaging market was valued at USD 32 billion in 2024 and is projected to reach USD 52 billion by 2033. The broader global primary pharmaceutical packaging market was estimated at USD 105.88 billion in 2023 and is projected to reach USD 206.03 billion by 2030.
Beauty + Home Segment
- Beauty and Personal Care Packaging (Pumps, Closures, Aerosol Valves): The global beauty and personal care packaging market is projected to grow from USD 41.3 billion in 2025 to USD 87.5 billion by 2035, at a CAGR of 7.8%. In 2025, plastics held 41.12% of the personal care packaging market share.
- Home Care Packaging (Pumps, Closures, Aerosol Valves): The global home care packaging market, valued at USD 40.87 billion in 2025, is anticipated to reach USD 71.75 billion by 2035.
- Aerosol Valves (across various applications including personal care and home care): The global aerosol valves market size was estimated at USD 1.64 billion in 2024 and is expected to grow to USD 2.86 billion in 2030. Another source indicates a market size of USD 1.93 billion in 2025, forecasted to reach USD 2.36 billion by 2031. Europe dominated this market in 2024, accounting for over 27.0% of the revenue. North America is also a significant market, holding approximately 40% of the global market share.
Food + Beverage Segment
- Dispensing and Non-Dispensing Closures: The global caps and closures market size was estimated at USD 111.01 billion in 2025 and is expected to reach USD 167.41 billion by 2033. The food segment held the largest revenue share of over 26.45% in 2025 within this market. Specifically for food, the global closures for food market was valued at USD 12.5 billion in 2024 and is projected to reach USD 18.7 billion by 2033. The global beverage caps and closures market is worth USD 51.22 billion in 2025 and is forecast to hit USD 63.40 billion by 2030.
- Aerosol Valves (for food and beverage markets): The global aerosol valves market, which includes food and beverage applications, was estimated at USD 1.64 billion in 2024 and is expected to grow to USD 2.86 billion in 2030.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for AptarGroup (ATR) over the Next 2-3 Years:
- Growth in Proprietary Drug Delivery Systems: AptarGroup anticipates continued strong growth within its Pharma segment, specifically driven by its proprietary drug delivery systems for injectables, systemic nasal drug delivery, and consumer healthcare solutions. This segment is considered pipeline-driven, with recent years seeing a high number of new product launches and opportunities added to the pipeline, supporting a long-term core sales target of 7% to 11% growth. The demand for injectable components, notably those related to GLP-1 drug delivery systems, has shown significant increases, further bolstering this driver.
- Strategic Acquisitions and CDMO Expansion: AptarGroup is expanding its capabilities and market reach through strategic acquisitions. For example, the acquisition of Mod3 Pharma's clinical trial manufacturing capabilities in July 2025 significantly enhances Aptar's Contract Development and Manufacturing Organization (CDMO) services for early-stage drug development, including an FDA-inspected facility. Additionally, the planned finalization of the Somaplast acquisition in Brazil in Q4 2025 is expected to bolster its pharma segment further.
- Development and Commercialization of Digital Health Solutions: The company's collaborations, such as the partnership with Sonmol in China and other Asian markets, are focused on developing digital therapies and services platforms, particularly for respiratory diseases. This initiative aims to expand platform services for remote patient monitoring, improve patient and physician interactions, and enhance treatment adherence and outcomes. Aptar's strategic investment in Sonmol further extends its collaboration into precision micron-scale drug delivery.
- Integration of Ultra-Pure Recycled Polypropylene (UPRP) and Sustainability Initiatives: AptarGroup's strategic partnership with PureCycle Technologies is focused on developing and incorporating ultra-pure recycled polypropylene (UPRP) into dispensing applications. Products utilizing PureFive resin are projected to be in production by late 2025 and available in stores by early 2026. This collaboration, alongside Aptar's broader commitment to making its dispensing solutions 100% reusable, recyclable, or compostable by 2025, aligns with growing market demand for sustainable packaging and supports a circular economy.
- Launch of Innovative New Products: AptarGroup consistently drives growth through innovation and new product introductions across its segments. Examples include the recently developed Unidose single-use liquid nasal delivery system, which has been utilized in the first FDA-approved intranasal loop diuretic for heart failure, demonstrating Aptar's capability in complex therapeutic areas and expanding its addressable market. Another innovation is the exclusive agreement with Bausch + Lomb for its Beat the Blink eye care delivery system. The company's extensive patent portfolio, with over 7,300 patents and pending patents, underscores its innovation-led approach.
AI Analysis | Feedback
Share Repurchases
- AptarGroup recently authorized a new share repurchase program of up to $600 million, which replaces all previous authorizations.
- For the full year 2025, the company repurchased 2.7 million shares totaling $365 million, marking the highest repurchase amount in the past decade.
- In 2025, AptarGroup returned $486 million to shareholders through share repurchases and dividends.
Capital Expenditures
- Capital expenditures for the full year 2025 decreased year-over-year, representing approximately 7% of sales.
- Capital investments for 2026 are projected to be in the range of $260 million to $280 million.
- The primary focus of these capital expenditures is on efficiency, prioritization of high-return investments, particularly in high-return pharma projects.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AptarGroup Earnings Notes | 12/26/2025 | |
| AptarGroup Stock Looks Undervalued, Ready to Move Up? | 11/05/2025 | |
| How Low Can AptarGroup Stock Really Go? | 10/17/2025 | |
| AptarGroup vs Alphabet: Which Is A Better Investment? | 08/18/2025 | |
| AptarGroup vs Newmont: Which Is A Better Investment? | 08/18/2025 | |
| How Does AptarGroup Stock Stack Up Against Its Peers? | 08/13/2025 | |
| Better Bet Than ATR Stock: Pay Less Than AptarGroup To Get More From DIS, MRK | 08/12/2025 | |
| Better Bet Than ATR Stock: Pay Less Than AptarGroup To Get More From NEU | 08/12/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 06/03/2026 | |
| Has AptarGroup Stock Quietly Become a Growth Opportunity? | 11/05/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 85.36 |
| Mkt Cap | 10.4 |
| Rev LTM | 7,032 |
| Op Inc LTM | 701 |
| FCF LTM | 391 |
| FCF 3Y Avg | 351 |
| CFO LTM | 664 |
| CFO 3Y Avg | 680 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.4% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 11.8% |
| QoQ Delta Rev Chg LTM | 2.8% |
| Op Inc Chg LTM | 13.2% |
| Op Inc Chg 3Y Avg | 9.3% |
| Op Mgn LTM | 11.4% |
| Op Mgn 3Y Avg | 11.3% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 10.4% |
| CFO/Rev 3Y Avg | 11.7% |
| FCF/Rev LTM | 6.2% |
| FCF/Rev 3Y Avg | 6.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.4 |
| P/S | 1.0 |
| P/Op Inc | 9.7 |
| P/EBIT | 11.6 |
| P/E | 19.3 |
| P/CFO | 11.6 |
| Total Yield | 7.1% |
| Dividend Yield | 1.6% |
| FCF Yield 3Y Avg | 5.1% |
| D/E | 0.7 |
| Net D/E | 0.6 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 19.5% |
| 3M Rtn | 12.6% |
| 6M Rtn | 11.9% |
| 12M Rtn | 2.8% |
| 3Y Rtn | 11.1% |
| 1M Excs Rtn | 18.8% |
| 3M Excs Rtn | -2.9% |
| 6M Excs Rtn | 4.4% |
| 12M Excs Rtn | -15.8% |
| 3Y Excs Rtn | -62.7% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharma | 1,738 | 1,644 | 1,522 | 1,372 | |
| Beauty | 1,338 | 1,253 | 1,297 | 1,246 | |
| Closures | 737 | 722 | 707 | 748 | |
| Intersegment Sales | -36 | -36 | -39 | -44 | |
| Aptar Pharma | 1,285 | ||||
| Beauty + Home | 1,434 | ||||
| Food + Beverage | 509 | ||||
| Total | 3,777 | 3,583 | 3,487 | 3,322 | 3,227 |
| $ Mil | 2015 | 2008 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|
| Aptar Pharma | 211 | 127 | |||
| Beauty & Home | 99 | 92 | |||
| Food and Beverage | 43 | ||||
| elimination | -28 | ||||
| Closures | 45 | ||||
| Other | -37 | ||||
| Dispensing Systems | 153 | 143 | 126 | ||
| SeaquistPerfect | 21 | 18 | 15 | ||
| Corporate & Other | -18 | -16 | |||
| Total | 324 | 227 | 174 | 143 | 125 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharma | 2,284 | 2,058 | 2,112 | 1,873 | |
| Beauty | 1,692 | 1,392 | 1,412 | 1,399 | |
| Closures | 799 | 746 | 766 | 780 | |
| Corporate & Other | 478 | 236 | 162 | 152 | |
| Aptar Pharma | 1,834 | ||||
| Beauty + Home | 1,616 | ||||
| Corporate & Other, unallocated | 118 | ||||
| Food + Beverage | 574 | ||||
| Total | 5,253 | 4,432 | 4,452 | 4,203 | 4,141 |
Price Behavior
Price Behavior
| Market Price | $126.98 | |
| Market Cap ($ Bil) | 8.1 | |
| First Trading Date | 04/23/1993 | |
| Distance from 52W High | -20.6% | |
| 50 Days | 200 Days | |
| DMA Price | $119.27 | $124.79 |
| DMA Trend | down | down |
| Distance from DMA | 6.5% | 1.8% |
| 3M | 1YR | |
| Volatility | 25.5% | 25.8% |
| Downside Capture | -15.14 | 45.73 |
| Upside Capture | -3.75 | 8.88 |
| Correlation (SPY) | 20.2% | 25.8% |
ATR Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.01 | 0.11 | 0.44 | 0.71 | 0.53 | 0.63 |
| Up Beta | 0.56 | 0.82 | 1.24 | 1.43 | 1.15 | 0.84 |
| Down Beta | 0.96 | 0.64 | 0.39 | 0.97 | 0.61 | 0.54 |
| Up Capture | -2% | -18% | 3% | 28% | 7% | 21% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 23 | 34 | 63 | 124 | 400 |
| Down Capture | -90% | -43% | -6% | 39% | 54% | 81% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 18 | 28 | 61 | 127 | 348 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATR | |
|---|---|---|---|---|
| ATR | -19.1% | 25.7% | -0.85 | - |
| Sector ETF (XLB) | 17.2% | 17.5% | 0.75 | 50.3% |
| Equity (SPY) | 21.7% | 12.5% | 1.29 | 25.9% |
| Gold (GLD) | 23.1% | 27.7% | 0.73 | 14.1% |
| Commodities (DBC) | 21.3% | 18.6% | 0.90 | -18.2% |
| Real Estate (VNQ) | 13.6% | 13.8% | 0.68 | 43.9% |
| Bitcoin (BTCUSD) | -42.0% | 42.7% | -1.15 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATR | |
|---|---|---|---|---|
| ATR | -0.7% | 22.6% | -0.08 | - |
| Sector ETF (XLB) | 6.9% | 19.0% | 0.25 | 59.6% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 52.3% |
| Gold (GLD) | 17.9% | 18.3% | 0.79 | 13.0% |
| Commodities (DBC) | 6.9% | 19.5% | 0.25 | 4.1% |
| Real Estate (VNQ) | 3.1% | 18.9% | 0.06 | 49.1% |
| Bitcoin (BTCUSD) | 12.2% | 53.8% | 0.41 | 19.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATR | |
|---|---|---|---|---|
| ATR | 6.4% | 22.1% | 0.26 | - |
| Sector ETF (XLB) | 10.3% | 20.7% | 0.44 | 61.3% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 57.1% |
| Gold (GLD) | 12.1% | 16.1% | 0.61 | 7.3% |
| Commodities (DBC) | 5.7% | 18.0% | 0.25 | 10.8% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 52.4% |
| Bitcoin (BTCUSD) | 59.0% | 66.2% | 0.99 | 13.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -3.8% | 1.6% | -8.8% |
| 2/5/2026 | 8.3% | 13.3% | 7.9% |
| 10/30/2025 | -6.7% | -6.6% | -2.2% |
| 7/31/2025 | -10.0% | -10.6% | -11.4% |
| 5/1/2025 | 2.5% | 3.4% | 5.8% |
| 2/6/2025 | -8.5% | -8.7% | -3.8% |
| 10/24/2024 | 1.4% | 0.8% | 3.0% |
| 7/25/2024 | 3.7% | 3.9% | 6.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 16 | 16 | 14 |
| # Negative | 8 | 8 | 10 |
| Median Positive | 2.3% | 2.8% | 5.4% |
| Median Negative | -5.2% | -5.5% | -2.7% |
| Max Positive | 8.3% | 13.3% | 11.8% |
| Max Negative | -10.0% | -10.6% | -11.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -3.8% | 1.6% | -8.8% |
| 2/5/2026 | 8.3% | 13.3% | 7.9% |
| 10/30/2025 | -6.7% | -6.6% | -2.2% |
| 7/31/2025 | -10.0% | -10.6% | -11.4% |
| 5/1/2025 | 2.5% | 3.4% | 5.8% |
| 2/6/2025 | -8.5% | -8.7% | -3.8% |
| 10/24/2024 | 1.4% | 0.8% | 3.0% |
| 7/25/2024 | 3.7% | 3.9% | 6.3% |
| 4/25/2024 | 2.2% | 4.1% | 5.6% |
| 2/8/2024 | 5.2% | 2.2% | 8.0% |
| 10/25/2023 | 0.9% | 0.5% | 5.0% |
| 7/27/2023 | 3.9% | 1.4% | 7.1% |
| 4/27/2023 | 1.7% | 2.2% | -1.8% |
| 2/16/2023 | 5.4% | 3.7% | 1.9% |
| 10/27/2022 | 2.1% | -4.4% | 4.5% |
| 7/28/2022 | -0.1% | -1.3% | -3.2% |
| 4/28/2022 | 2.4% | 0.6% | -2.9% |
| 2/17/2022 | 2.4% | 4.6% | 2.6% |
| 10/28/2021 | -4.1% | 2.0% | -0.1% |
| 7/30/2021 | 0.8% | -0.1% | 5.2% |
| 4/30/2021 | 1.1% | 4.5% | -2.6% |
| 2/18/2021 | -6.2% | -7.6% | -1.2% |
| 10/29/2020 | 1.0% | 8.8% | 11.8% |
| 7/30/2020 | -2.3% | -0.2% | 0.2% |
| SUMMARY STATS | |||
| # Positive | 16 | 16 | 14 |
| # Negative | 8 | 8 | 10 |
| Median Positive | 2.3% | 2.8% | 5.4% |
| Median Negative | -5.2% | -5.5% | -2.7% |
| Max Positive | 8.3% | 13.3% | 11.8% |
| Max Negative | -10.0% | -10.6% | -11.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/01/2026 | 10-Q |
| 12/31/2025 | 02/06/2026 | 10-K |
| 09/30/2025 | 10/31/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/07/2025 | 10-K |
| 09/30/2024 | 10/25/2024 | 10-Q |
| 06/30/2024 | 07/26/2024 | 10-Q |
| 03/31/2024 | 04/26/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| 06/30/2022 | 07/29/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/01/2026 | 10-Q |
| 12/31/2025 | 02/06/2026 | 10-K |
| 09/30/2025 | 10/31/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/07/2025 | 10-K |
| 09/30/2024 | 10/25/2024 | 10-Q |
| 06/30/2024 | 07/26/2024 | 10-Q |
| 03/31/2024 | 04/26/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| 06/30/2022 | 07/29/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 02/18/2022 | 10-K |
| 09/30/2021 | 10/29/2021 | 10-Q |
| 06/30/2021 | 07/30/2021 | 10-Q |
| 03/31/2021 | 04/30/2021 | 10-Q |
| 12/31/2020 | 02/19/2021 | 10-K |
| 09/30/2020 | 10/30/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/01/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 11/01/2019 | 10-Q |
| 06/30/2019 | 08/01/2019 | 10-Q |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Adjusted EPS | 1.32 | 1.36 | 1.4 | 16.2% | Higher New | Guidance: 1.17 for Q1 2026 | |
| Q2 2026 Effective Tax Rate | 22.5% | 23.5% | 24.5% | ||||
Prior: Q4 2025 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Adjusted EPS | 1.13 | 1.17 | 1.21 | -5.6% | Lower New | Guidance: 1.24 for Q4 2025 | |
| 2026 Capital Expenditures | 260.00 Mil | 270.00 Mil | 280.00 Mil | ||||
Insider Activity
Updated 6/16/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prieur, Marc | Segment President | Direct | Sell | 6102026 | 115.58 | 5,000 | 577,895 | 2,233,332 | Form |
| 2 | Vinczeller, Shiela | Chief Human Resources Officer | Direct | Sell | 6052026 | 112.61 | 3,555 | 400,341 | 3,049,351 | Form |
| 3 | Gong, Xiangwei | President, Asia | Direct | Sell | 5272026 | 116.13 | 4,200 | 487,765 | 1,251,233 | Form |
| 4 | Hudson, Irene Elizabeth | EVP and Chief Legal Officer | Direct | Sell | 5082026 | 123.43 | 1,264 | 156,012 | 182,673 | Form |
| 5 | Touya, Gael | Segment President | Direct | Sell | 2192026 | 141.35 | 3,500 | 494,739 | 3,952,679 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prieur, Marc | Segment President | Direct | Sell | 6102026 | 115.58 | 5,000 | 577,895 | 2,233,332 | Form |
| 2 | Vinczeller, Shiela | Chief Human Resources Officer | Direct | Sell | 6052026 | 112.61 | 3,555 | 400,341 | 3,049,351 | Form |
| 3 | Gong, Xiangwei | President, Asia | Direct | Sell | 5272026 | 116.13 | 4,200 | 487,765 | 1,251,233 | Form |
| 4 | Hudson, Irene Elizabeth | EVP and Chief Legal Officer | Direct | Sell | 5082026 | 123.43 | 1,264 | 156,012 | 182,673 | Form |
| 5 | Touya, Gael | Segment President | Direct | Sell | 2192026 | 141.35 | 3,500 | 494,739 | 3,952,679 | Form |
| 6 | Prieur, Marc | Segment President | Direct | Sell | 2112026 | 137.81 | 2,000 | 275,620 | 1,894,198 | Form |
| 7 | Ackerman, Daniel | Chief Accounting Officer | Direct | Sell | 12152025 | 121.23 | 15,000 | 1,818,435 | 3,589,227 | Form |
| 8 | Touya, Gael | Segment President | Direct | Sell | 9122025 | 136.12 | 2,500 | 340,298 | 4,282,716 | Form |
| 9 | Vinczeller, Shiela | Chief Human Resources Officer | Direct | Sell | 9082025 | 137.97 | 1,167 | 161,006 | 3,467,640 | Form |
| 10 | Prieur, Marc | Segment President | Direct | Sell | 6162025 | 152.80 | 2,000 | 305,606 | 2,405,880 | Form |
| 11 | Chainey, Kimberly | EVP and Chief Legal Officer | Direct | Sell | 6102025 | 152.79 | 1,671 | 255,318 | 1,694,172 | Form |
| 12 | Touya, Gael | Segment President | Direct | Sell | 6092025 | 152.62 | 3,300 | 503,654 | 5,183,514 | Form |
Industry Resources
| Materials Resources |
| Chemical & Engineering News (C&EN) |
| Mining.com |
| Plastics News |
| Metal, Glass & Plastic Containers Resources |
| Packaging Digest |
| Packaging World |
| Plastics Today |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/5/2026